Abstract
Mucosal drug delivery is considered as a convenient, mild and safe route, especially for the treatment of chronic diseases. In general, mucosal routes include buccal, ocular, intranasal, pulmonary, vaginal and oral delivery. To increase the efficiency of mucosal delivery, nanocarriers have been extensively explored, of which lipidbased nanocarriers attract much attention due to their great biocompatibility, cell membrane affinity and other excellent physicochemical properties by using different kinds of lipids. However, the effectiveness of lipid-based nanocarriers is limited by numerous in vivo physiological barriers (e.g. chemical environment, mucus and epithelium) in tracts or cavities. Herein, modification strategies of these nanocarriers are widely investigated and show great improvement of drug bioavailability. The aim of this review is to introduce applications of lipid-based nanocarriers in different mucosal routes and discuss typical modification strategies.
Keywords: Lipid-based nanocarriers, modification strategies, mucosal delivery, absorption barriers.
Current Pharmaceutical Design
Title:Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Volume: 21 Issue: 36
Author(s): Lei Wu, Min Liu, Xi Zhu, Wei Shan and Yuan Huang
Affiliation:
Keywords: Lipid-based nanocarriers, modification strategies, mucosal delivery, absorption barriers.
Abstract: Mucosal drug delivery is considered as a convenient, mild and safe route, especially for the treatment of chronic diseases. In general, mucosal routes include buccal, ocular, intranasal, pulmonary, vaginal and oral delivery. To increase the efficiency of mucosal delivery, nanocarriers have been extensively explored, of which lipidbased nanocarriers attract much attention due to their great biocompatibility, cell membrane affinity and other excellent physicochemical properties by using different kinds of lipids. However, the effectiveness of lipid-based nanocarriers is limited by numerous in vivo physiological barriers (e.g. chemical environment, mucus and epithelium) in tracts or cavities. Herein, modification strategies of these nanocarriers are widely investigated and show great improvement of drug bioavailability. The aim of this review is to introduce applications of lipid-based nanocarriers in different mucosal routes and discuss typical modification strategies.
Export Options
About this article
Cite this article as:
Wu Lei, Liu Min, Zhu Xi, Shan Wei and Huang Yuan, Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery, Current Pharmaceutical Design 2015; 21 (36) . https://dx.doi.org/10.2174/1381612821666150923103000
DOI https://dx.doi.org/10.2174/1381612821666150923103000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism The Management and Outcomes of Pharmacological Treatments for Tinnitus
Current Neuropharmacology Ivabradine: A Current Overview
Current Clinical Pharmacology Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Acetylcysteine Therapy for Acetaminophen Poisoning
Current Pharmaceutical Biotechnology Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Current Drug Safety Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design siRNA Silencing of Gene Expression in Trabecular Meshwork: RhoA siRNA Reduces IOP in Mice
Current Molecular Medicine New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design Discovery and Advancement of Farnesyl Transferase Inhibitors as Potential Anticancer Therapeutic Agents: SCH 66336 a Case Study
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology An Insight into the Therapeutic Potential of Major Coffee Components
Current Drug Metabolism Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Effect of Piperine, Quercetin, Polysorbate 80 on the Oral Bioavailability of Losartan in Male Wistar Rats
Pharmaceutical Nanotechnology